News

FORMA News

FORMA Therapeutics Appoints Kenneth W. Bair to Head Research and Development

June 29, 2009

Dr. Bair Brings 30 Years of Oncology Drug Discovery, Development and Chemistry Experience to FORMA. Read full story

FORMA Therapeutics Strengthens Scientific Advisory Board with Addition of Three Leaders from Industry and Academia

March 30, 2009

FORMA Therapeutics announced today the addition of three new members to the Company’s Scientific Advisory Board (SAB). Read full story

FORMA Therapeutics and Experimental Therapeutics Centre of Singapore Collaborate to Develop Therapeutics Against a Broad Range of Novel Targets

March 16, 2009

FORMA Therapeutics and the Experimental Therapeutics Centre of Singapore (ETC) announced today a collaboration agreement to leverage FORMA’s transformative chemistry platform to discover novel compounds for further development by ETC. Read full story

FORMA Therapeutics Collaborates with Cubist Pharmaceuticals to Discover and Develop Novel Antibacterial Drugs

January 26, 2009

FORMA Therapeutics announced today that it has signed a collaboration agreement with Cubist Pharmaceuticals, Inc. to leverage FORMA’s transformative chemistry platform to discover novel antibacterial compounds for development by Cubist. Read full story

FORMA Therapeutics Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions

January 12, 2009

FORMA Therapeutics announced today that it has entered into a license and option agreement through the Novartis Option Fund. Read full story

Leading Researchers Establish FORMA Therapeutics to Integrate Transformative Biology and Chemistry to Address Challenging Targets and Develop Breakthrough Oncology Drugs

January 6, 2009

FORMA Therapeutics announced today its debut as an integrated, global drug discovery company. Read full story

Researchers find new molecule to block ‘Hedgehog’ signaling in cancer, development

January 18, 2009

Researchers have achieved a feat drug developers had thought difficult, if not impossible, discovering a compound that blocks the functioning of a key developmental protein by binding to an “undruggable” target — an advance that may provide a new avenue to fight skin, pancreatic, prostate, and other cancers. Read full story in Harvard Science

Organic Chemistry: Molecular diversity by design

January 8, 2009

Many organic syntheses are target-oriented — each multi-step route is designed to make just one compound. But now a diversity-oriented synthesis can make 80 different molecular skeletons in just a few steps. By Stuart Schreiber; Nature 457, 153-154. Read full story

Landmark genomic study of lung cancer published in Nature

October 22, 2008

Work draws upon several large-scale methods, reveals key molecular defects shared with other cancers. Broad Institute, Cambridge MA. Read full story

Charting the genome’s landscape

September 7, 2008

New map of human genetic variation refines researchers’ view of gene copy number. Broad Institute, Cambridge MA. Read full story

Cancer genomics project begins to bear fruit

September 4, 2008

Large-scale study sheds light on mutations and core pathways in brain cancer. Broad Institute, Cambridge MA. Read full story